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Abstract
Background: Influenza is often not recognized as an important cause of severe or fatal disease in tropical and subtropical
countries in Southeast Asia. The extent to which Oseltamivir treatment may protect against a fatal outcome in severe
influenza infections is not known. Thailand’s National Avian Influenza Surveillance (NAIS) system affords a unique
opportunity to describe the epidemiology of laboratory-confirmed severe and fatal human influenza infections.
Methodology/Principal Findings: During January 2004 through December 2006, 11,641 notifications to the NAIS were
investigated in 73 of 76 Thai provinces. Clinical and demographic data and respiratory swab specimens were collected and
tested by PCR for influenza. Using the NAIS database, we identified all patients with laboratory confirmed human influenza
(A/H3N2, A/H1N1 and Type B) infection. A retrospective medical record review was conducted on all fatal cases with
laboratory confirmed influenza and from a sample of hospitalized cases in 28 provinces. The association of underlying risk
factors, Oseltamivir treatment and risk of a fatal outcome were examined. Human influenza infections were identified in
2,075 (18%) cases. Twenty-two (1%) deaths occurred including seven deaths in children less than ten years of age. Thirty-five
percent of hospitalized human influenza infections had chest X-ray confirmed pneumonia. Current or former smoking;
advanced age, hypertension and underlying cardiovascular, pulmonary or endocrine disease were associated with a fatal
outcome from human influenza infection. Treatment with Oseltamivir was statistically associated with survival with a crude
OR of .11 (95% CI: 0.04–0.30) and .13 (95% CI: 0.04–0.40) after controlling for age.
Conclusions: Severe and fatal human influenza infections were commonly identified in the NAIS designed to identify avian
A/H5N1 cases. Treatment with Oseltamivir is associated with survival in hospitalized human influenza pneumonia patients.
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Introduction
Influenza is a vaccine preventable viral respiratory infection and
an important cause of morbidity and mortality in temperate
climates, especially among the elderly and the very young [1,2]. In
the US, high quality data on the burden of severe and fatal
influenza infection has supported policies to expand vaccination
programs [3,4]. However in tropical and subtropical climates
comparatively little information on disease burden is available,
especially data describing severe influenza infections that result in
hospitalization or death [5]. The non-specific symptoms of
influenza infection and the lack of routine laboratory diagnostic
testing in most hospitals significantly limits case ascertainment and
reporting. In the absence of data on severe and fatal human
influenza infections, clinicians and the general public tend to
regard such severe infections as rare. The public health impact of
this perception can be significant as influenza antiviral medications
and vaccines are available but poorly utilized in many countries in
East and Southeast Asia [6]. Recently, research from Hong Kong
and Singapore using large mortality databases has suggested that
influenza-associated mortality rates are similar to those docu-
mented in the United States [7–9]. In less economically developed
countries in East and Southeast Asia, such research is hindered by
the lack of robust mortality registries and hospital admission
databases. Information on influenza disease burden is essential for
policy makers considering investment in control programs.
Outbreaks of avian influenza A/H5N1 virus occurred in poultry
in Thailand in late 2003 with human H5N1 cases first identified in
early 2004 [10]. In response the Thailand Ministry of Public
Health (MOPH) established the National Avian Influenza
Surveillance (NAIS) system in 2004. The system’s mandate was
the identification and prompt investigation of suspected human AI
infections in all provinces in all healthcare facilities nationwide
[11]. Under NAIS patients presenting with fever and respiratory
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H5N1 infection including 1) contact with sick or dead poultry
within 7 days before the symptom onset, 2) living in areas where
poultry die-offs had occurred within 14 days before symptoms
onset and 3) contact with any pneumonia patients in the 10 days
before symptoms onset.
If patients had risk factors or the physician suspected avian
influenza infection, nasopharyngeal swabs, throat swabs or
secretions from endotracheal suctions were collected from patients
and tested by RT-PCR for influenza A subtypes H1, H3, H5 and
influenza Type B at the Thailand National Institute of Health
(NIH) laboratory in Bangkok or at several regional NIH network
laboratories [12]. All H5N1 positive specimens and those from
rapidly progressive or fatal human influenza cases were confirmed
at the central NIH laboratory. Clinical and demographic data
were collected as part of case investigations. We analyzed data
from the NAIS and medical record reviews to describe the
epidemiology of laboratory-confirmed severe and fatal human
influenza infections in Thailand. Using a retrospective case-control
design, we also examined the association of underlying risk factors,
antiviral treatment and risk of a fatal outcome.
Methods
This research was carried our with approval from and in
compliance with the standards of the ethical review committees of
the Thailand Ministry of Public Health and the United States
Centers for Disease Control and Prevention. During January 2004
through December 2006, the NAIS system recorded 11,641 cases
requiring investigation for suspected H5N1 infection reported
from 73 of the 76 Thai provinces. All fatal human influenza cases
(A(H1N1), A(H3N2) or B) and non-fatal cases hospitalized for two
or more days were characterized as severe and eligible for on-site
medical record review. Human influenza-associated deaths were
patients reported by the NAIS with RT-PCR confirmed influenza
infection who died while in the hospital.
We selected the 28 provinces where at least one H5N1 case or
human influenza death had been detected by the NAIS. In these
28 provinces, the NAIS recorded 1,488 human influenza
infections. We selected all 22 fatal human influenza cases for
medical record review. Due to logistical and resource consider-
ations, we sampled a subset of the remaining 1,466 non-fatal
human influenza cases using an approach designed to insure that
non-fatal cases came from the same population as the fatal cases .
(Figure 1) First, we visited all hospitals where a fatal human
influenza case had been admitted. In most cases, these patients
had been transferred between 2 or 3 hospitals as their clinical
course deteriorated. We then attempted to review all nonfatal
human influenza cases from these hospitals. In a few cases the
hospital clerical staff was not able to locate all of the medical
records. Finally, we visited other small rural, district hospitals
located in the same provinces which had also reported non-fatal
human influenza cases to the NAIS and attempted to review all
available records.
Hospitals were contacted in advance and asked to prepare the
medical records for review. A standardized 8-page data collection
form was used to collect detailed epidemiological and clinical data
including underlying illnesses, smoking and HIV status. Two
trained study staff jointly conducted each medical record review.
Data were entered into a Microsoft Access database. We
conducted post data entry validation of all data fields to assure
that the electronic record was identical to the paper medical
record review form. We examined the crude, unadjusted
relationship of individual demographic, epidemiologic and clinical
characteristics in relation to risk of death from human influenza.
We used multivariable logistic regression to control for age and
estimate adjusted odds ratios of a fatal outcome among
hospitalized patients with human influenza infection. Specifically,
we compared the 22 fatal human influenza cases with the 423
nonfatal human influenza cases with respect to antiviral treatment
and underlying conditions (cardiovascular, hypertension, pulmo-
nary, endocrine disorders, renal disease, neurological disorders,
chronic gastrointestinal disease, cancer, and hematological disor-
ders).
Insufficient numbers of subjects were observed to have
gastrointestinal disease, cancer, hematological disorders, neuro-
logical disorders, renal disease, aspirin use or HIV-positive status
to evaluate the association of these conditions with a fatal
outcome. Furthermore, small numbers precluded evaluation of
more than two risk factors at a time. We also examined the
association of fatal outcome with age, gender, smoking status, and
antiviral treatment among human influenza cases. We calculated
odd ratios and 95% confidence intervals (CI) using SAS 9.1
software. We used exact logistical regression methods to calculate
adjusted odds ratios (ORs). Variables were coded using an
indicator variable for each category level except for the referent
level. The 10–19 year age group was selected as the reference
category after explanatory analysis revealed this category to have
the lowest risk of death. Similarly, current and former smoking was
coded with indicator variables with no smoking designated as the
referent category.
Results
In 2004 the NAIS recorded 2,846 case investigations including
106 deaths nationwide. In 2005 there were 3,199 investigations
and 158 deaths while in 2006 there were 5,596 investigations with
177 deaths. In this population of 11,641 persons, 2,075 (18%)
laboratory-confirmed human influenza infections and 22 influen-
za-associated deaths were identified. Human influenza infections
were identified in 73 of the 76 Thai provinces while H5N1
infections were localized to the central and northern regions where
most commercial poultry production is located. (Figure 2) In total,
we reviewed medical records from 445 human influenza cases
admitted to 93 hospitals in 28 Thai provinces. Information on
comorbidities was missing on only three individuals, one of which
was a fatality. The mean age of sampled cases was 22 years
(median 13) and 57% were male. Very young children and the
elderly were underrepresented in the study sample compared to
other populations under active pneumonia surveillance in Thai-
land [13,14]. In 2004, subtype A/H1N1 accounted for 36%, A/
H3N2 for 38% and Influenza type B accounted for 27% of all
infections. In 2005, 50% of human influenza infections were due
to A/H3N2 and 43% were due to Influenza B, while the A/H1N1
subtype caused 79% of infections in 2006. (Table 1)
Influenza A/H3N2 caused 8 deaths, subtype A/H1N1 caused 7
deaths and type B caused 7 deaths. Seven (32%) of deaths
occurred in children less than 10 years of age, 5 (23%) in patients
aged 10–49 years and 10 (45%) of deaths occurred in patients 50
years of age or older. Fifteen (71%) fatal cases had at least one
underlying illness. The most frequently documented underlying
illness was hypertension (6), followed by cardiovascular disease (4),
pulmonary disease (4) and endocrine disorders (4). Twenty-one
(95%) of the fatal cases were diagnosed with a lower respiratory
tract infection (LRTI). The median time from onset of illness until
death was 6.5 days (mean 10.7, range 1–68 days). Five (22%)
patients with fatal infections had bacterial co-infections reported
including 2 cases with Burkholderia pseudomallei, 2 cases with
Influenza and Oseltamivir
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the 423 nonfatal human influenza infections, 340 (80%) were
diagnosed with an LRTI. The median duration of illness was 5
days (1–22 days) and the median length of hospital stay was 3 days
(range 1–21). There were 150 (35%) chest X-ray confirmed
pneumonia cases and 3 of these required endotracheal intubation
and intensive care. Among those with a diagnosis of LRTI, 41
(27%) were children 0–5 years while 10 (7%) cases were $60 years
of age.
The age distribution of sampled cases was slightly older than the
non-sampled cases but the gender distribution was similar.
(Table 2) Compared to nonfatal cases, cases with a fatal outcome
were more likely to have an underlying cardiovascular disease,
hypertension, chronic pulmonary disease, and endocrine disorders
although only hypertension remained significant after adjustment
for age. (Table 3) Death was associated with female gender but this
did not reach statistical significance. Previous or current smoking
was significantly associated with a fatal outcome but this did not
reach statistical significance after controlling for age. Death was
associated with advanced age and the 10–19 year age group
experienced the fewest fatal cases.
Sixty-three percent of patients were treated with Oseltamivir in
2004, 64% in 2005 and 77% in 2006 (p=.01). Overall, 5 (1.5%) of
318 patients treated with Oseltamivir died compared with 17 (5%)
fatal outcomes among 131 patients who did not receive treatment.
Antiviral treatment with Oseltamivir was statistically associated
with survival with a crude OR with Oseltamivir treatment of .11
(95%CI: 0.04–0.30) and .13 (95%CI: 0.04–0.40) after controlling
for age. Oseltamivir was also associated with survival when
controlling for the potential confounding variables cardiovascular
disease (OR 0.13; 95% CI 0.04–0.38) and hypertension (OR 0.14;
95% CI 0.04–0.44) (data not shown). The mean time from onset of
Figure 1. Sample selection process.
doi:10.1371/journal.pone.0006051.g001
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doi:10.1371/journal.pone.0006051.g002
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cases was 4 days (median 4, range 2–7,) compared to 2.62 days
(median 2, range 0–13) in the 303 surviving patients. Two of the 5
fatal cases who received Oseltamivir treatment died within 2 days
of hospital admission.
Discussion
In response to concerns regarding A/H5N1 and the raised
pandemic threat, Thailand’s NAIS system was rapidly established
with a high-quality laboratory diagnostic system that enabled the
country to quickly identify a small number of human AI cases
among thousands of suspected infections [12]. While each new
case of AI received global media attention, the NAIS system
identified approximately 80 times as many human influenza
infections. More deaths resulted from these infections than from
H5N1 (22 versus 17). The surveillance population under the NAIS
system was restricted mainly to persons with acute respiratory
illness who had a recent history of exposure to sick or dying
poultry. In this limited population of 11,641 persons, 2,075 cases
of human influenza were identified. Twenty-two deaths were
identified that would have otherwise gone unrecognized by the
existing passive surveillance system for human influenza. In
contrast to the NAIS, between 1999 and 2003 the Thailand
national routine passive surveillance system reported only 3 deaths
due to human influenza infection. During 2004–2006, a single
influenza-associated death was reported through routine passive
surveillance in the Thai population of 65 million persons [15].
This under-ascertainment can be explained by the lack of
laboratory diagnostic capacity for influenza in nearly all public
hospitals and to a common misperception among Thai clinicians
that influenza is neither common nor severe.
The NAIS case definition included exposure to sick or dying
poultry and consequently very young children and the elderly were
underrepresented in our sample. As these age groups are at
increased risk for serious complications, the NAIS would not have
captured many severe and fatal human influenza infections. Our
sampling strategy involved sampling non-fatal cases from the same
provinces where fatal human influenza cases (or H5N1 cases) had
been reported to best approximate the population from which fatal
cases arise. This approach resulted in some small though
statistically significant differences in the age structure between
sampled and non-sampled cases. Potential variability in the age
distribution of the population that each hospital serves could
explain these differences.
We observed a statistically significant survival benefit associated
with Oseltamivir treatment among patients hospitalized with
influenza. This potentially important finding should be interpreted
with caution. Although Oseltamivir has been shown to reduce
symptom duration, complications and hospitalization among adult
outpatients as well as decrease lower respiratory tract infections in
observational studies [16–20], evidence of a survival benefit from
Oseltamivir treatment for human influenza infection has been
infrequently reported [21]. Our small, retrospective, observational
study has limitations with respect to establishing causality and we
Table 1. Human influenza cases and deaths reported by National Avian Influenza Surveillance.
2004 2005 2006
Reported Cases
(%) Reviewed Deaths
1
Reported
Cases (%) Reviewed Deaths
Reported
Cases (%) Reviewed Deaths
A/H1 104 (36) 27 (40%) 1 40 (8) 14 (10%) 1 981 (79) 178 (74%) 5
A/H3 110 (38) 28 (42%) 1 264 (50) 87 (63%) 5 108 (9) 28 (12%) 2
Type B 78 (27) 12 (17%) 1 230 (43) 37 (27%) 3 160 (13) 34 (14%) 3
Total 292 67 3 534 138 9 1249 240 10
1All deaths also reviewed.
doi:10.1371/journal.pone.0006051.t001
Table 2. Age and gender distribution of sampled cases compared to all cases reported to NAIS in 28 provinces.
Variables Sampled Cases (#, %) All Other NAIS Cases (#, %) Total in 28 Provinces
Age
0–4 81 (18) 182 (17) 263
5–9 98 (22) 285 (27) 383
10–19 101 (23) 238 (23) 339
20–59 135 (30) 302 (29) 437
60+ 30 (7) 36 (3) 66
Chi Square for Age Distribution P=0.02
Gender
Male 259 (58) 574 (55) 833 (56)
Female 186 (42) 469 (45) 655 (44)
Chi square for Gender Distribution P=0.26
Total 445 1043 1488
doi:10.1371/journal.pone.0006051.t002
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of illness scores which may have confounded or biased our results.
However, the strength and significance of these data indicate a
survival benefit from Oseltamivir treatment in hospitalized
influenza patients. More research is needed to verify these findings
which could influence pneumonia case management approaches
as well as strategies for antiviral use during a pandemic.
Outside of Singapore and Hong Kong, no epidemiological
studies of human influenza-associated mortality have been
published in Southeast Asia [5]. The 22 deaths we uncovered
probably represent only a small fraction of human influenza-
associated mortality in Thailand during 2004–2007 given the
narrowly defined criteria for testing based on risk factors for
H5N1. Although data on influenza–associated mortality in
Thailand are not available, a few recent studies provide insight
into the contribution of influenza to inpatient pneumonia and
outpatient febrile respiratory illness in Thailand [22,23]. While the
precise figure varies from year to year, approximately 8–10% of
hospitalized pneumonia cases in Thailand are attributed to human
influenza infection [24,25]. In our study, 35% of all hospitalized
Table 3. Factors associated with a fatal outcome.
Outcome Unadjusted Age Adjusted
Fatal Non-Fatal OR 95% CI OR* 95% CI
Year
2004 3 (14%) 64(15%) 1.08 0.29–4.03 1.21 0.20–5.09
2005 9 (41%) 129 (31%) 1.60 0.64–3.80 1.66 0.57–4.81
2006 10 (45%) 230(54%) 1 ref 1 ref
chi-sq 0.59
Antiviral Treatment
No Oseltamivir 17 (77%) 113 (27%) 1 ref 1 ref
Oseltamivir 5 (23%) 310 (73%) 0.11 0.04–0.30 0.13 0.04–0.40
chi-sq ,0.0001
Comorbidities
No Cardiovascular disease 17 (81%) 408 (97%) 1 ref 1 ref
Cardiovascular disease 4 (19%) 13 (3%) 7.38 2.18–25.04 4.04 1.08–15.11
chi-sq 0.0002
No Hypertension 15 (71%) 407(97%) 1 ref 1 ref
Hypertension 6 (29%) 14 (3%) 11.63 3.92–34.46 4.67 1.03–20.85
chi-sq ,0.0001
No Chronic pulmonary disease 17 (81%) 401 (95%) 1 ref 1 ref
Chronic pulmonary disease 4 (19%) 20 (5%) 4.72 1.45–15.32 3.11 0.64–11.76
chi-sq 0.0048
No Endocrine disorder 17 (81%) 414 (98%) 1 ref 1 ref
Endocrine disorder 4 (19%) 7 (2%) 13.92 3.71–52.13 5.01 0.84–26.56
chi-sq ,0.0001
Gender
Male 10 (45%) 249 (59%) 1 ref 1 ref
Female 12 (55%) 174 (41%) 1.72 0.73–4.06 1.7 0.63–4.55
chi-sq 0.21
Tobacco
Never 15(75%) 385(93%) 1 ref 1 ref
Current 3(15%) 18(4%) 4.3 1.1–16.1 1.93 0.28–10.01
Former 2(10%) 10(2%) 5.1 1.0–25.5 2.08 0.17–14.28
chi-sq 0.006
Age
0 to 9 7 (32%) 172 (41%) 4.1 0.5–33.6 -
10 to 19 1 (5%) 100 (24%) 1 ref
20–49 4 (18%) 99 (23%) 4.0 0.4–36.8 -
50 plus 10 (45%) 52 (12%) 19.2 2.4–154.4 -
chi-sq 0.0001
*Age Adjusted ORs calculated using Exact Logistic Regression methods.
doi:10.1371/journal.pone.0006051.t003
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pneumonia. Studies from other regional countries report that 11–
26% of outpatients with febrile respiratory illness have influenza
virus infections [5].
In conclusion, our findings suggest that the national passive
surveillance system substantially underreports the burden of severe
and fatal human influenza infection in Thailand and that
treatment with Oseltamivir may provide a survival benefit in
these patients. The elderly, smokers and persons with underlying
comorbidities with human influenza infection are at increased risk
of a fatal outcome. Further research on influenza-associated
mortality and Oseltamivir treatment using national hospital
discharge, mortality and influenza surveillance databases is needed
to inform influenza control policies, guide clinical management
and support pandemic preparedness planning.
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